DaVita stock rises 23.46% to a new 52-week high

9 articles · Updated · MarketWatch · May 6

Shares closed at $193.88 on Wednesday, topping the previous $159.42 peak set on 2 March, with trading volume reaching 2.9 million.
The gain marked DaVita's third straight daily advance and far outpaced rivals including UnitedHealth and Icon, while Quest Diagnostics fell.
The jump came during a broadly positive US market session, with the S&P 500 up 1.46% and the Dow Jones Industrial Average rising 1.24%.

With its stock soaring past analyst targets, has DaVita's value-based care model permanently justified its new valuation?

As DaVita's stock hits a record high, why is its largest investor, Berkshire Hathaway, selling off millions of shares?

DaVita’s care model is thriving while government programs lag. What is its secret to making value-based kidney care profitable?